PR Newswire09.20.18
NuVasive Inc., a company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, announced it will highlight the Company's latest disruptive spine technology at the North American Spine Society (NASS) Annual Meeting held September 26-29, 2018 in Los Angeles, Calif., at the Los Angeles Convention Center.
"Now more than ever, NuVasive is expanding its portfolio with innovative launches covering spine's leading procedures, materials, and systems," said Gregory T. Lucier, chairman and chief executive officer of NuVasive. "NuVasive is fully committed to furthering its R&D investment and bringing disruptive technology to market to meet the needs of our surgeon partners to provide better and more predictable outcomes for patients."
At the annual meeting, NuVasive will highlight its commitment to developing spine precision surgery advancements in key focus areas:
"Now more than ever, NuVasive is expanding its portfolio with innovative launches covering spine's leading procedures, materials, and systems," said Gregory T. Lucier, chairman and chief executive officer of NuVasive. "NuVasive is fully committed to furthering its R&D investment and bringing disruptive technology to market to meet the needs of our surgeon partners to provide better and more predictable outcomes for patients."
At the annual meeting, NuVasive will highlight its commitment to developing spine precision surgery advancements in key focus areas:
- Surgical Intelligence is an ecosystem of integrated, modular technologies to deliver safer, faster and smarter surgery. A key part of this ecosystem is LessRay, a stand-alone proprietary technology that enhances low-dose, low-radiation fluoroscopy (or x-ray) images to have similar diagnostic capabilities as conventional full-dose fluoroscopy images. With the evolution of Surgical Intelligence, LessRay will integrate into the Pulse surgical automation platform, a first-of-its-kind integrated spine system addressing a broad range of clinical challenges, with enhanced utility and intuitive workflow. This platform introduces 2D- and 3D-navigation and smart imaging capabilities along with the Company's leading neuromonitoring, NuvaMap O.R. surgical planning, radiation reduction, and patient-specific rod-bending technologies. Both systems will be available for live demonstrations at the meeting.
- Lateral Single-Position Solutions are intended to decrease the amount of time a patient is under anesthesia and increase operating room efficiency by reducing the need for patient repositioning. This is built on the foundation of the Company's XLIF procedure and is supported by extensive clinical evidence with more than 400 peer-reviewed, XLIF-specific publications. NuVasive's proprietary instrumentation and fixation expand the benefits of lateral surgery to more spinal levels from T6-S1, compared to traditional lateral procedures, by providing direct access to the L5-S1 level from a lateral position.
- Advanced Materials Science (AMS) Interbody Portfolio is designed to deliver enhanced osseointegration and biomechanics through innovative implant design and superior surface, structure, and imaging characteristics. The Company's recently launched TLX 20 degree expandable spinal interbody implant with a first-of-its-kind oblique profile designed for transforaminal lumbar interbody fusion (TLIF) procedures will be on display, and demonstrates the Company's commitment for further development of a full suite of expandable cage technologies. NuVasive is the only company to offer four specific materials for spinal interbodies: traditional PEEK (polyetheretherketone), propriety porous PEEK, titanium and 3D-printed porous titanium.
- Intraoperative Neuromonitoring (IONM): For the first time, the NASS Annual Meeting will include an IONM symposium where surgeons can learn more about the utility, evidence, and value of neuromonitoring in spine surgery, along with moderated abstract presentations. NuVasive's clinical services division is the nation's largest provider of outsourced IONM services, and the Company will demonstrate its neuromonitoring capabilities through its Pulse platform.